Enhertu (fam-trastuzumab deruxtecan-nxki) vs Orserdu (elacestrant)
Enhertu (fam-trastuzumab deruxtecan-nxki) vs Orserdu (elacestrant)
Enhertu (fam-trastuzumab deruxtecan-nxki) is an antibody-drug conjugate specifically designed for the treatment of HER2-positive breast cancer, targeting the HER2 protein and delivering chemotherapy directly to the cancer cells. Orserdu (elacestrant), on the other hand, is a selective estrogen receptor degrader (SERD) indicated for the treatment of estrogen receptor-positive (ER+) breast cancer, which works by binding to the estrogen receptor and degrading it, thus inhibiting the growth of cancer cells. When deciding between Enhertu and Orserdu, it is crucial to consider the specific type of breast cancer involved, as the effectiveness of each medication is dependent on the cancer's receptor status (HER2-positive for Enhertu and ER-positive for Orserdu), and to consult with a healthcare provider for a personalized treatment plan.
Difference between Enhertu and Orserdu
Metric | Enhertu (fam-trastuzumab deruxtecan-nxki) | Orserdu (elacestrant) |
---|---|---|
Generic name | Fam-trastuzumab deruxtecan-nxki | Elacestrant |
Indications | HER2-positive breast cancer | ER+/HER2- advanced or metastatic breast cancer |
Mechanism of action | HER2-directed antibody and topoisomerase inhibitor conjugate | Estrogen receptor antagonist |
Brand names | Enhertu | Orserdu |
Administrative route | Injection | Oral |
Side effects | Nausea, fatigue, vomiting, alopecia, constipation, decreased appetite, anemia, neutropenia, diarrhea, leukopenia, cough, and thrombocytopenia | Hot flush, nausea, fatigue, musculoskeletal pain, and vomiting |
Contraindications | History of interstitial lung disease or pneumonitis | Not specified |
Drug class | Antibody-drug conjugate | Selective estrogen receptor degrader (SERD) |
Manufacturer | Daiichi Sankyo and AstraZeneca | Radiant Pharmaceuticals |
Efficacy
Enhertu (fam-trastuzumab deruxtecan-nxki) for Breast Cancer
Enhertu, also known by its generic name fam-trastuzumab deruxtecan-nxki, is a targeted therapy used for the treatment of breast cancer. Specifically, it is indicated for adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The efficacy of Enhertu was demonstrated in a pivotal phase II trial, where it showed a significant improvement in objective response rate (ORR) and progression-free survival (PFS) compared to other treatments. Patients treated with Enhertu experienced a higher rate of response to therapy, indicating a reduction in tumor size, and a longer duration before the disease progressed, which underscores its efficacy in this patient population.
Orserdu (elacestrant) for Breast Cancer
Orserdu, with the generic name elacestrant, is a selective estrogen receptor degrader (SERD) that has shown promise in the treatment of estrogen receptor-positive (ER+), HER2-negative advanced or metastatic breast cancer. Orserdu is particularly evaluated for patients who have received prior endocrine therapy. Clinical trials assessing the efficacy of Orserdu have indicated that it can provide a clinical benefit in terms of PFS in this subset of breast cancer patients. The drug's efficacy is highlighted by its ability to target and degrade the estrogen receptor, thereby inhibiting the growth of cancer cells that rely on this pathway.
Comparative Efficacy in Breast Cancer Treatment
When comparing Enhertu and Orserdu, it is essential to consider that they target different subtypes of breast cancer and mechanisms of action. Enhertu is focused on HER2-positive cases and acts as an antibody-drug conjugate, delivering cytotoxic agents directly to cancer cells. In contrast, Orserdu is used for ER+, HER2-negative breast cancer and functions by disrupting the estrogen receptor signaling pathway. Both medications have shown efficacy in their respective indications and represent significant advancements in the personalized treatment of breast cancer. The choice between these therapies would depend on the specific molecular characteristics of the breast cancer being treated.
Conclusion
Both Enhertu and Orserdu have made substantial contributions to the treatment landscape of breast cancer, offering new hope for patients with specific subtypes of the disease. The efficacy of Enhertu in HER2-positive breast cancer and Orserdu in ER+, HER2-negative breast cancer has been supported by clinical trials, which demonstrate their roles in improving patient outcomes. As research continues, these medicines may further establish themselves as key components of breast cancer therapy, potentially improving survival rates and quality of life for many patients.
Regulatory Agency Approvals
Enhertu
Orserdu
Access Enhertu or Orserdu today
If Enhertu or Orserdu are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us